Pamela Craig - Merck Independent Director

MRK Stock  EUR 136.80  1.60  1.16%   

Director

Ms. Pamela J. Craig serves as Independent Directorof the Company. She served as the chief financial officer of Accenture, a global management consulting, technology services and outsourcing company, from 2006 until her retirement in 2013. During her 34 years at Accenture, she held a variety of consulting, line management, operational and finance leadership roles. Ms. Craig is currently a senior advisor for Teneo, a global advisory firm since 2015.
Age 62
Tenure 9 years
Professional MarksMBA
Phone49 6151 72 0
Webhttps://www.merckgroup.com
Craig is a Phi Beta Kappa graduate of Smith College and earned an MBA from New York University. She serves as a member of the board of directors of Akamai Technologies, a leading worldwide provider of internet optimization services, where she also serves as audit committee chair and as a member of the compensation committee. She also serves as a board member and M&A committee member of VMware, Inc., a global technology leader in virtualization and cloud infrastructure. Additionally, Ms. Craig serves on the board of directors and audit committee of WalMart Stores, Inc.

Merck Management Efficiency

The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
Merck Company has accumulated 7.93 B in total debt with debt to equity ratio (D/E) of 0.65, which is about average as compared to similar companies. Merck Company has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

DIRECTOR Age

Juyan LiuGuangzhou Baiyunshan Pharmaceut
59
Art GarciaElanco Animal Health
58
Wenqi JiangGuangzhou Baiyunshan Pharmaceut
61
Weihong WangGuangzhou Baiyunshan Pharmaceut
56
Hong LiGuangzhou Baiyunshan Pharmaceut
56
Changhai WuGuangzhou Baiyunshan Pharmaceut
57
Chunbo ZhangGuangzhou Baiyunshan Pharmaceut
42
Shou ChaoCanSino Biologics
56
Xiaoping ChuGuangzhou Baiyunshan Pharmaceut
63
Xianrong HuangGuangzhou Baiyunshan Pharmaceut
57
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. MERCK KGAA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 57850 people. Merck Company (MRK) is traded on Frankfurt Exchange in Germany and employs 63,723 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Matthias Heinzel, CEO Board
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Gerhard Schmitz, Head Accounting
Christine Seidman, Independent Director
Kathy Warden, Independent Director
Constantin Fest, Head Relations
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Peter Guenter, CEO Board
Barbara Weiland, Chief Officer
Belen MD, Chair CEO
Marcus Kuhnert, CFO Board
Peter Wendell, Independent Director
Friederike Rotsch, Group Compliance
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Dirk Toepfer, Chief Officer
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Senior Vice President - Finance, Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Kai Beckmann, CEO Board
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Merck Stock

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.